Pregnancy outcomes in patients from a Scottish Adult Cystic Fibrosis Unit taking elexacaftor/tezacaftor/ivacaftor, 2020-present.

IF 0.5 Q4 OBSTETRICS & GYNECOLOGY

Obstetric Medicine Pub Date : 2025-02-26 DOI:10.1177/1753495X251319588

Ivaila Valcheva, Iona Paterson

{"title":"Pregnancy outcomes in patients from a Scottish Adult Cystic Fibrosis Unit taking elexacaftor/tezacaftor/ivacaftor, 2020-present.","authors":"Ivaila Valcheva, Iona Paterson","doi":"10.1177/1753495X251319588","DOIUrl":null,"url":null,"abstract":"Background: Elexacaftor/tezacaftor/ivacaftor (ETI) was made available to eligible women in September 2020 by NHS Scotland.Methods: Retrospective data collection for the 13 pregnancies in women taking ETI from the West of Scotland Adult Cystic Fibrosis Unit, September 2020-December 2023.Results: Mean pre-pregnancy FEV1 was 2.26L, 70% predicted (range 1.25-3.19); (38-86% predicted). Mean FEV1 post-pregnancy was 2.29L, 71% predicted (range 1.49-3.40); (45-92% predicted). The mean age at conception (29 years) and mean percentage predicted FEV1 (70%) were higher than in other UK studies. Two pregnancies resulted in miscarriage, the remaining 11 pregnancies resulted in a live birth. Seven women had a pulmonary exacerbation of CF during pregnancy. Three of four women with FEV1 < 60% predicted had uncomplicated pregnancies with no pulmonary exacerbations.Conclusion: We demonstrate that people with CF and varying spectrums of lung disease who take CFTR modulators can have uncomplicated pregnancies with positive lung function outcomes.","PeriodicalId":51717,"journal":{"name":"Obstetric Medicine","volume":" ","pages":"1753495X251319588"},"PeriodicalIF":0.5000,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11866333/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obstetric Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/1753495X251319588","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Elexacaftor/tezacaftor/ivacaftor (ETI) was made available to eligible women in September 2020 by NHS Scotland.

Methods: Retrospective data collection for the 13 pregnancies in women taking ETI from the West of Scotland Adult Cystic Fibrosis Unit, September 2020-December 2023.

Results: Mean pre-pregnancy FEV1 was 2.26L, 70% predicted (range 1.25-3.19); (38-86% predicted). Mean FEV1 post-pregnancy was 2.29L, 71% predicted (range 1.49-3.40); (45-92% predicted). The mean age at conception (29 years) and mean percentage predicted FEV1 (70%) were higher than in other UK studies. Two pregnancies resulted in miscarriage, the remaining 11 pregnancies resulted in a live birth. Seven women had a pulmonary exacerbation of CF during pregnancy. Three of four women with FEV1 < 60% predicted had uncomplicated pregnancies with no pulmonary exacerbations.

Conclusion: We demonstrate that people with CF and varying spectrums of lung disease who take CFTR modulators can have uncomplicated pregnancies with positive lung function outcomes.

查看原文本刊更多论文

2020年至今苏格兰成人囊性纤维化病房患者服用elexaftor /tezacaftor/ivacaftor的妊娠结局

背景：苏格兰NHS于2020年9月向符合条件的妇女提供Elexacaftor/tezacaftor/ivacaftor （ETI）。方法：回顾性收集2020年9月至2023年12月在苏格兰西部成人囊性纤维化病房接受ETI治疗的13例妊娠妇女的数据。结果：孕前平均FEV1为2.26L，预测70% (1.25 ~ 3.19)；(38 - 86%预测)。妊娠后平均FEV1为2.29L，预测71%（范围1.49 ~ 3.40）；预测(45 - 92%)。平均受孕年龄（29岁）和平均预测FEV1百分比（70%）高于英国其他研究。两次怀孕导致流产，其余11次怀孕导致活产。7名妇女在怀孕期间发生CF肺加重。结论：我们证明患有CF和各种肺部疾病的人服用CFTR调节剂可以获得肺功能阳性的无并发症妊娠。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Obstetric Medicine OBSTETRICS & GYNECOLOGY-

CiteScore

1.90

自引率

0.00%

发文量